Development of Smoothened Agonist Non Phospholipid Liposomal Nanoparticles for Bone Repair
Technical Report,15 Jul 2018,14 Jul 2019
Johns Hopkins University Baltimore United States
Pagination or Media Count:
Non-healing bone defects remain a significant problem for combat casualties and military veterans. A principle challenge is to develop therapeutic agents that safely and effectively improve growth and differentiation factor GDF based skeletal regeneration. The manipulation of Hedgehog signaling is a promising alternative to BMP2 for improved bone repair outcomes. Recently, we observed thatthe small molecule Hedgehog agonist SAG demonstrates pro-osteogenic pro-vasculogenic effects to induce mouse calvarial defect healing. Independently, we have developed innately osteoinductive Stearylamine and Oxysterol SAOxy nanoparticles NPs, and showed their high drug loading efficiency and synergistic osteoinductive potential with the small molecule SAG. In the current proposal, we willcombine these recent breakthroughs to develop a next generation NP packaged small molecule as a bone graft substitute product to jumpstart endogenous bone repair.
- Anatomy and Physiology